Caris Life Sciences insider plans 478K share sale
Executive David Spetzler has filed a Rule 144 notice to sell 478,000 Caris Life Sciences shares tied to exercising expiring stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Caris Life Sciences, Inc. (CAI) reports that David Spetzler has filed a notice of proposed sale of company common stock under Rule 144. The notice covers 478,000 shares of common stock, expected to be sold on September 3, 2026 in connection with the exercise of stock options under a registered plan.
The sales are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, with settlement in cash. Spetzler notes he is selling sufficient shares to cover the option exercise cost and related taxes for an expiring option.
Key Figures
Key Terms
Rule 144 regulatory
Exercise of Options Under a Registered Plan financial
expiring option financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for Caris Life Sciences (CAI)?
When is the CAI stock sale under this Form 144 expected to occur?
AI-generated analysis. How Rhea-AI works. Not financial advice.